title: Serum CXCL12 Levels as a Novel Predictor of Future Stroke Recurrence in Patients with Acute Ischemic Stroke.
abstract: Previous studies had shown that CXC chemokine ligand-12 (CXCL12) plays a significant role in animal models of ischemic stroke, but its role in human stroke is unclear. The aim of this study was to test the relationship between elevated serum circulating CXCL12 levels and the 1-year stroke recurrence in Chinese patients with acute ischemic stroke (AIS). All consecutive patients with first-ever acute ischemic stroke from January 2011 to September 2013 were recruited to participate in the study. Serum levels of CXCL12 and National Institute of Health Stroke Scale (NIHSS) were measured at the time of admission. Logistic regression analysis was used to evaluate the stroke recurrence according to serum CXCL12 levels. Receiver operating characteristic (ROC) curve was used to evaluate the accuracy of serum CXCL12 in predicting stroke recurrence. Clinical follow-up was performed at 1 year. In our study, 248 patients finished the 1-year follow-up. At 1-year follow-up, 31 patients had a recurrence ischemic stroke. The median CXCL12 levels were significantly higher in those who sustained a recurrence ischemic stroke compared with those who did not [24.2 ng/mL (IQR 15.4-33.7) vs 6.5 ng/mL (IQR 3.4-10.2); Z = 8.258, P < 0.0001]. In multivariate analysis, there was an increased risk of stroke recurrence associated with serum CXCL12 levels ≥12.15 ng/mL (OR 9.122, 95 % CI 6.103-15.104) after adjusting for above possible confounders. The time to recurrence stroke distribution between patients with baseline CXCL12 levels ≥12.15 ng/mL and those with baseline CXCL12 levels <12.15 ng/mL were significantly different (P < 0.0001, log-rank test). Elevated circulating CXCL12 levels at admission are strongly associated with the future recurrence of ischemic stroke in Chinese patients with AIS. Further studies are warranted to confirm this association and define the role for CXCL12 as a novel predictor biomarker for stroke recurrence.
authors.affiliation: Department of Neurology, The People's Hospital of Laiwu City, No. 1, Xuehudajie, Changshao North Road, Laiwu, 271100, Shandong Province, China. neurokim011@126.com.
authors.forename: Xiao-Lin
authors.initials: XL
authors.lastname: Gu
authors.affiliation: Department of Neurology, The People's Hospital of Laiwu City, No. 1, Xuehudajie, Changshao North Road, Laiwu, 271100, Shandong Province, China.
authors.forename: Lin
authors.initials: L
authors.lastname: Liu
authors.affiliation: Department of Neurosurgery, The People's Hospital of Laiwu City, Laiwu, 271100, Shandong Province, China.
authors.forename: Xiang-Dong
authors.initials: XD
authors.lastname: Lu
authors.affiliation: Department of Neurosurgery, The People's Hospital of Laiwu City, Laiwu, 271100, Shandong Province, China.
authors.forename: Zhen-Rui
authors.initials: ZR
authors.lastname: Liu
mesh_terms: D000368:Aged; D002545:Brain Ischemia / Q000097:blood* / Q000150:complications*; D054377:Chemokine CXCL12 / Q000097:blood*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D053208:Kaplan-Meier Estimate; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D012372:ROC Curve; D012008:Recurrence; D020521:Stroke / Q000097:blood* / Q000150:complications*
chemical_list: C515255:CXCL12 protein, human; D054377:Chemokine CXCL12
keywords: Acute ischemic stroke; CXC chemokine ligand-12; Predictor; Recurrence
references.citation: Curr Drug Targets. 2012 Feb;13(2):166-72
references.pmid: 22204316
references.citation: Lancet Neurol. 2004 Jul;3(7):391-3
references.pmid: 15207791
references.citation: Eur Neurol. 2012;67(6):363-9
references.pmid: 22614671
references.citation: Stroke. 1991 Mar;22(3):312-8
references.pmid: 2003301
references.citation: Stroke. 1993 Jan;24(1):35-41
references.pmid: 7678184
references.citation: J Neuroimmunol. 2008 Jul 31;198(1-2):39-45
references.pmid: 18513805
references.citation: Inflammation. 2014 Jun;37(3):686-93
references.pmid: 24292801
references.citation: Stroke. 2012 Dec;43(12):3382-6
references.pmid: 23042661
references.citation: Mol Neurobiol. 2015 Feb;51(1):230-9
references.pmid: 24691546
references.citation: Arch Intern Med. 2005 Nov 28;165(21):2479-84
references.pmid: 16314544
references.citation: Bull World Health Organ. 1976;54(5):541-53
references.pmid: 1088404
references.citation: Lancet. 1991 Jun 22;337(8756):1521-6
references.pmid: 1675378
references.citation: Mol Neurobiol. 2016 Apr;53(3):1509-1517
references.pmid: 25650122
references.citation: Eur J Neurol. 2012 Mar;19(3):395-401
references.pmid: 21951424
references.citation: Nat Immunol. 2001 Feb;2(2):108-15
references.pmid: 11175802
references.citation: Stroke. 2011 Mar;42(3):618-25
references.pmid: 21257825
references.citation: Prog Neurobiol. 2008 Feb;84(2):116-31
references.pmid: 18177992
references.citation: Mol Neurobiol. 2016 Jan;53(1):677-685
references.pmid: 25520003
references.citation: PLoS One. 2014 Apr 11;9(4):e94845
references.pmid: 24728374
references.citation: J Neuropathol Exp Neurol. 2004 Jan;63(1):84-96
references.pmid: 14748564
references.citation: Circ Res. 2000 Feb 4;86(2):131-8
references.pmid: 10666407
references.citation: Neurology. 2009 Jun 16;72(24):2104-10
references.pmid: 19528517
references.citation: Stroke. 2009 Apr;40(4):1237-44
references.pmid: 19246697
references.citation: Circ J. 2010 Mar;74(3):418-23
references.pmid: 20118565
references.citation: Stroke. 1989 Jul;20(7):864-70
references.pmid: 2749846